Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,162,300 papers from all fields of science
Search
Sign In
Create Free Account
tedisamil
Known as:
3,7-di-(cyclopropylmethyl)-9,9-tetramethylene-3,7-diazabicyclo(3.3.1)nonane
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (4)
Anti-Arrhythmia Agents
Bridged Bicyclo Compounds, Heterocyclic
Cardiotonic Agents
Cyclopropanes
Narrower (1)
KC 8857
Tedisamil Sesquifumarate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Atrial fibrillation: from ion channels to bedside treatment options.
Bramahn . Singh
Journal of Electrocardiology
2009
Corpus ID: 21389573
Review
2008
Review
2008
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Emily L Conway
,
S. Musco
,
P. Kowey
American Journal of Cardiology
2008
Corpus ID: 9802001
Review
2001
Review
2001
Tedisamil: master switch of nature?
S. Doggrell
Expert Opinion on Investigational Drugs
2001
Corpus ID: 23771631
Decreasing heart rate is potentially useful in ischaemic heart disease. Tedisamil is a bradycardic agent resulting from its…
Expand
1998
1998
Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes.
J. Faivre
,
S. Rouanet
,
A. Bril
Journal of Cardiovascular Pharmacology
1998
Corpus ID: 22304267
The modulation of the protein kinase A-activated chloride current (PKA-I[Cl]) may lead to modification of the cardiac action…
Expand
1998
1998
Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation.
Gregory S. Friedrichs
,
J. Nelson Abreu
,
E. Driscoll
,
J. Borlak
,
Benedict R. Lucchesi
Journal of Cardiovascular Pharmacology
1998
Corpus ID: 9728713
The electrophysiologic and antifibrillatory properties of tedisamil (KC-8857) were studied in vivo in a conscious canine model of…
Expand
Review
1997
Review
1997
Emerging Class III Antiarrhythmic Agents:Mechanism of Action and Proarrhythmic Potential
L. A. Nair
,
A. Grant
Cardiovascular Drugs and Therapy
1997
Corpus ID: 32325404
The goal of developing an antiarrhythmic agent effective against malignant ventricular arrhythmias while maintaining a low side…
Expand
1997
1997
Frequency-dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol
M. Németh
,
A. Varró
,
L. Virág
,
O. Hála
,
D. Thormählen
,
Julius Gyula Papp
Journal of Cardiovascular Pharmacology and…
1997
Corpus ID: 37323700
Background: Tedisamil is a potent bradycardic/antiischemic drug known to lengthen car diac repolarization by blocking various…
Expand
1996
1996
Effects of tedisamil (KC‐8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart
L. Chi
,
James L. Park
,
+4 authors
B. Lucchesi
British Journal of Pharmacology
1996
Corpus ID: 16590233
1 The direct cardiac electrophysiological and antifibrillatory actions of tedisamil (KC‐8857) were studied in rabbit isolated…
Expand
Review
1994
Review
1994
ION CHANNEL MODULATORS AS POTENTIAL POSITIVE INOTROPIC COMPOUNDS FOR TREATMENT OF HEART FAILURE
S. Doggrell
,
A. Hoey
,
Lindsay Brown
Clinical and Experimental Pharmacology and…
1994
Corpus ID: 23821931
1. Current positive inotropy therapy of heart failure is associated with major problems: digoxin and the phosphodiesterase…
Expand
Highly Cited
1991
Highly Cited
1991
Influence of Tedisamil on the Initiation and Maintenance of Ventricular Fibrillation: Chemical Defibrillation by Ito Blockade?
K. Tsuchihashi
,
M. Curtis
Journal of Cardiovascular Pharmacology
1991
Corpus ID: 30360407
We examined the effects of tedisamil on ventricular fibrillation (VF) elicited by regional ischemia and by reperfusion in…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required